Luis Toro

Dr. Luis Toro


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2022 in Life
Verified
Journal Article
Open access
PDF file
APAlfredo Parra-Lucares
Alfredo Parra-Lucares
PHPaula Segura Hidalgo
Paula Segura Hidalgo
VRVerónica Rojas
Verónica Rojas
CPCatalina Pumarino
Catalina Pumarino
GSGustavo Enrique Saint-Pierre
Gustavo Enrique Saint-Pierre
LTLuis Toro
Luis Toro
The COVID-19 pandemic has had a significant global impact, with more than 280,000,000 people infected and 5,400,000 deaths. The use of personal protective equipment and the anti-SARS-CoV-2 vaccination campaigns have reduced infection and death rates worldwide. However, a recent increase in infection rates has been observed associated with the appearance of SARS-CoV-2 variants, including the more recently described lineage B.1.617.2 (Delta variant) and lineage B.1.1.529/BA.1 (Omicron variant). These new variants put the effectiveness of international vaccination at risk, with the appearance of new outbreaks of COVID-19 throughout the world. This emergence of new variants has been due to multiple predisposing factors, including molecular characteristics of the virus, geographic and environmental conditions, and the impact of social determinants of health that favor the genetic diversification of SARS-CoV-2. We present a literature review on the most recent information available on the emergence of new variants of SARS-CoV-2 in the world. We analyzed the biological, geographical, and sociocultural factors that favor the development of these variants. Finally, we evaluate the surveillance strategies for the early detection of new variants and prevent their distribution outside these regions.

17 May 2019 in Journal of Bone and Mineral Research
Verified
Journal Article
Closed access
PDF file
ÁDÁngela Delucchi
Ángela Delucchi
LTLuis Toro
Luis Toro
RARodrigo Alzamora
Rodrigo Alzamora
VBVictor Barrientos
Victor Barrientos
MGMagdalena González
Magdalena González
LMLuis Michea
Luis Michea

13 December 2021 in Viruses
Verified
Journal Article
Open access
PDF file
APAlfredo Parra-Lucares
Alfredo Parra-Lucares
LTLuis Toro
Luis Toro
SMSebastian Ignacio Weitz Muñoz
Sebastian Ignacio Weitz Muñoz
CRCristóbal Ramos
Cristóbal Ramos
The SARS-CoV-2 pandemic has mobilized many efforts worldwide to curb its impact on morbidity and mortality. Vaccination of the general population has resulted in the administration of more than 6,700,000,000 doses by the end of October 2021, which is the most effective method to prevent hospitalization and death. Among the adverse effects described, myocarditis and pericarditis are low-frequency events (less than 10 per 100,000 people), mainly observed with messenger RNA vaccines. The mechanisms responsible for these effects have not been specified, considering an exacerbated and uncontrolled immune response and an autoimmune response against specific cardiomyocyte proteins. This greater immunogenicity and reactogenicity is clinically manifested in a differential manner in pediatric patients, adults, and the elderly, determining specific characteristics of its presentation for each age group. It generally develops as a condition of mild to moderate severity, whose symptoms and imaging findings are self-limited, resolving favorably in days to weeks and, exceptionally, reporting deaths associated with this complication. The short- and medium-term prognosis is favorable, highlighting the lack of data on long-term evolution, which should be determined in longer follow-ups.

1 April 2020 in Revista médica de Chile
Verified
Journal Article
Open access
PDF file
LTLuis Toro
Luis Toro
APAlfredo Parra
Alfredo Parra
MAMiriam Alvo
Miriam Alvo
La actual pandemia de COVID-19 que estamos viviendo a nivel nacional e internacional ha tenido múltiples efectos en nuestra sociedad. Uno de los más importantes corresponde al temor que genera en la población la consulta en los servicios de urgencias del país dada la posibilidad de contraer esta enfermedad y las limitaciones de movilización por la falta de transporte y controles sanitarios. Debido a esto, existe un potencial riesgo en la población por la disminución de consultas por condiciones distintas de la infección por SARS-CoV-2 que pueden llegar a causar elevada morbilidad y mortalidad, especialmente el caso de las enfermedades cardiovasculares como los síndromes coronarios agudos y accidentes cerebrovasculares, que ocupan los primeros puestos de mortalidad en la población general en nuestro país1

3 October 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
LTLuis Toro
Luis Toro
VRVerónica Rojas
Verónica Rojas
CCCarolina Conejeros
Carolina Conejeros
PAPatricia Ayala
Patricia Ayala
APAlfredo Parra-Lucares
Alfredo Parra-Lucares
LMLuis Michea
Luis Michea
Acute Kidney Injury (AKI) is a frequent complication in intensive care unit (ICU) patients that increases mortality and chronic kidney disease (CKD) development. AKI is associated with elevated plasma fibroblast growth factor 23 (FGF23), which can be modulated by erythropoietin (EPO) and Klotho. We aimed to evaluate whether a combined biomarker that includes these molecules predicted short-/long-term outcomes. We performed a prospective cohort of ICU patients with sepsis and previously normal renal function. They were followed during their inpatient stay and for one year after admission. We measured plasma FGF23, EPO, and Klotho levels at admission and calculated a combined biomarker (FEK). A total of 164 patients were recruited. Of these, 50 (30.5%) had AKI at admission, and 55 (33.5%) developed AKI within 48 h. Patients with AKI at admission and those who developed AKI within 48 h had 12- and 5-fold higher FEK values than non-AKI patients, respectively. Additionally, patients with higher FEK values had increased 1-year mortality (41.9% vs. 18.6%, p = 0.003) and CKD progression (26.2% vs. 8.3%, p = 0.023). Our data suggest that the FEK indicator predicts the risk of AKI, short-/long-term mortality, and CKD progression in ICU patients with sepsis. This new indicator can improve clinical outcome prediction and guide early therapeutic strategies.

16 September 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
RCRene Clavero
Rene Clavero
APAlfredo Parra-Lucares
Alfredo Parra-Lucares
GMGabriel Méndez-Valdés
Gabriel Méndez-Valdés
Gabriel Méndez-ValdésGabriel Méndez-Valdés
Gabriel Méndez-Valdés
KBKarin Bravo
Karin Bravo
LTLuis Toro
Luis Toro
The CoronaVac vaccine is the most used anti-SARS-CoV-2 vaccine worldwide. Previous data indicate that this vaccine produces a lower immune response than RNA vaccines such as BNT162b2. End-stage renal disease (ESRD) patients have an increased rate of COVID-19 and a reduced immune response to vaccinations. Currently, there is little data on this population’s immune response induced by CoronaVac. Methods: This study involved a prospective cohort of ESRD patients in chronic hemodialysis who received a two-dose immunization scheme of either CoronaVac (Sinovac Biotech) or BNT162b2 vaccines (Pfizer-BioNTech). We measured the plasma levels of anti-SARS-CoV-2 IgG antibodies. We determined antibody titers before immunization, 2 and 4 months after two doses, plus 4 months after a booster dose. Results: We evaluated 208 patients in three hemodialysis centers. The mean age was 62.6 ± 15.6 years, of whom 91 were female (41.75%). Eighty-one patients (38.94%) received the BNT162b2 vaccine and 127 (61.06%) received the CoronaVac vaccine. Patients who received the BNT162b2 vaccine had a higher humoral response compared to those who received the CoronaVac vaccine (4 months after the second dose: BNT162b2: 88.89%, CoronaVac: 51.97%, p < 0.001; 4 months after the booster: BNT162b2: 98.77%, CoronaVac: 86.61%, p < 0.001). Conclusions: Our results suggest that the CoronaVac vaccine induced a lower humoral response than the BNT162b2 vaccine in ESRD patients on hemodialysis.